AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2023
Feb 4, 2023
32559_dirs_2023-02-03_356a2855-82af-44b9-b393-c0963bbddf8f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2023-02-01
Reporting Person: Sundaram Senthil Vel (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-30 | Common Stock | P | 3.00 | $1.41 | Acquired | 7659.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | Stock Option (Right to Buy) | $8.94 | A | 900000.00 | Acquired | 2033-01-31 | Common Stock (900000.00) | Direct |
Footnotes
F1: Includes the purchase of 3 shares under the Terns Employee Stock Purchase Plan on November 30, 2022.
F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.